Document:

Exhibit 10.2

 

REGISTRATION
RIGHTS AGREEMENT

 

This
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 23, 2021, is by and
between Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and BioHiTech
Global, Inc., a Delaware corporation (the “Company”).

 

RECITALS

 

A.         The
Company and the Investor have entered into that certain Common Stock Purchase Agreement, dated as of the date hereof (the “Purchase
Agreement”), pursuant to which the Company may issue, from time to time, to the Investor up to the lesser of (i) $20,000,000
in aggregate gross purchase price of newly issued shares of the Company’s common stock, par value $0.0001 per share (“Common
Stock”), and (ii) the Exchange Cap (to the extent applicable under Section 3.3 of the Purchase Agreement), as
provided for therein.

 

B.          Pursuant
to the terms of, and in consideration for the Investor entering into, the Purchase Agreement, the Company shall cause to be issued to
the Investor the Commitment Shares in accordance with the terms of the Purchase Agreement.

 

C.          Pursuant
to the terms of, and in consideration for the Investor entering into, the Purchase Agreement, and to induce the Investor to execute and
deliver the Purchase Agreement, the Company has agreed to provide the Investor with certain registration rights with respect to the Registrable
Securities (as defined herein) as set forth herein.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein and in the Purchase
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be
legally bound hereby, the Company and the Investor hereby agree as follows:

 

		1.	Definitions.

 

Capitalized terms used herein
and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement. As used in this Agreement, the
following terms shall have the following meanings:

 

(a)            “Agreement”
shall have the meaning assigned to such term in the preamble of this Agreement

 

(b)            “Allowable
Grace Period” shall have the meaning assigned to such term in Section 3(p).

 

(c)            “Blue
Sky Filing” shall have the meaning assigned to such term in Section 6(a).

 

     

     

    

 

(d)           “Business
Day” means any day other than Saturday, Sunday or any other day on which commercial banks in New York, New York are authorized
or required by law to remain closed.

 

(e)            “Claims”
shall have the meaning assigned to such term in Section 6(a).

 

(f)            “Closing
Date” shall mean the date of this Agreement.

 

(g)            “Commission”
means the U.S. Securities and Exchange Commission or any successor entity.

 

(h)            “Common
Stock” shall have the meaning assigned to such term in the recitals to this Agreement.

 

(i)            “Company”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

(j)            “Effective
Date” means the date that the applicable Registration Statement has been declared effective by the Commission.

 

(k)           “Effectiveness
Deadline” means (i) with respect to the Initial Registration Statement required to be filed to pursuant to Section 2(a),
the earlier of (A) the 90th calendar day after the date of this Agreement, if such Registration Statement is subject to
review by the Commission, and (B) the 30th calendar day after the date of this Agreement, if the Company is notified (orally
or in writing, whichever is earlier) by the Commission that such Registration Statement will not be reviewed and (ii) with respect
to any New Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the earlier of (A) the
90th calendar day following the date on which the Company was required to file such additional Registration Statement, if such
Registration Statement is subject to review by the Commission, and (B) the 30th calendar day following the date on which
the Company was required to file such New Registration Statement, if the Company is notified (orally or in writing, whichever is earlier)
by the Commission that such Registration Statement will not be reviewed.

 

(l)           “Filing
Deadline” means (i) with respect to the Initial Registration Statement required to be filed to pursuant to Section 2(a),
the 30th Business Day after the date of this Agreement and (ii) with respect to any New Registration Statements that may
be required to be filed by the Company pursuant to this Agreement, the 20th Business Day following the sale of substantially
all of the Registrable Securities included in the Initial Registration Statement or the most recent prior New Registration Statement,
as applicable, or such other date as permitted by the Commission.

 

(m)           “Indemnified
Damages” shall have the meaning assigned to such term in Section 6(a).

 

(n)           “Initial
Registration Statement” shall have the meaning assigned to such term in Section 2(a).

 

    2 

     

    

 

(o)            “Investor”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

(p)            “Investor
Party” and “Investor Parties” shall have the meaning assigned to such terms in Section 6(a).

 

(q)            “Legal
Counsel” shall have the meaning assigned to such term in Section 2(b).

 

(r)            “New
Registration Statement” shall have the meaning assigned to such term in Section 2(c).

 

(s)          “Person”
means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company,
trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.

 

(t)            “Prospectus”
means the prospectus in the form included in the Registration Statement, as supplemented from time to time by any Prospectus Supplement,
including the documents incorporated by reference therein.

 

(u)           “Prospectus
Supplement” means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule 424(b) under
the Securities Act, including the documents incorporated by reference therein.

 

(v)            “Purchase
Agreement” shall have the meaning assigned to such term in the recitals to this Agreement.

 

(w)           “register,”
 “registered,” and “registration” refer to a registration effected by preparing and
filing one or more Registration Statements in compliance with the Securities Act and pursuant to Rule 415 and the declaration of
effectiveness of such Registration Statement(s) by the Commission.

 

(x)            “Registrable
Securities” means all of (i) the Initial Purchase Shares, (ii) the Shares, (iii) the Commitment Shares (including
all of the Initial Commitment Shares and all of the Additional Commitment Shares), and (iv) any capital stock of the Company issued
or issuable with respect to such Initial Purchase Shares, Shares or Commitment Shares, including, without limitation, (1) as a result
of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of the
Company into which the shares of Common Stock are converted or exchanged and shares of capital stock of a successor entity into which
the shares of Common Stock are converted or exchanged, in each case until such time as such securities cease to be Registrable Securities
pursuant to Section 2(f).

 

(y)            “Registration
Statement” means a registration statement or registration statements of the Company filed under the Securities Act covering
the resale by the Investor of Registrable Securities, as such registration statement or registration statements may be amended and supplemented
from time to time, including all documents filed as part thereof or incorporated by reference therein.

 

(z)            “Registration
Period” shall have the meaning assigned to such term in Section 3(a).

 

    3 

     

    

 

(aa)     “Rule 144”
means Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any
other similar or successor rule or regulation of the Commission that may at any time permit the Investor to sell securities of the
Company to the public without registration.

 

(bb)    “Rule 415”
means Rule 415 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any
other similar or successor rule or regulation of the Commission providing for offering securities on a delayed or continuous basis.

 

(cc)     “Staff”
shall have the meaning assigned to such term in Section 2(e).

 

(dd)     “Violations”
shall have the meaning assigned to such term in Section 6(a).

 

		2.	Registration.

 

(a)            Mandatory
Registration. The Company shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with the
Commission the Initial Registration Statement on Form S-1 (or any successor form) covering the resale by the Investor of (i) all
of the Initial Purchase Shares, (ii) all of the Initial Commitment Shares, (iii) 200,000 Additional Commitment Shares, representing
the maximum number of Additional Commitment Shares issuable pursuant to the Purchase Agreement, if any, to be issued and delivered to
the Investor under Section 10.1(ii)(b) of the Purchase Agreement, and (iv) the maximum number of additional Registrable
Securities (which shall be designated in the Initial Registration Statement as Shares that may be issued and sold by the Company to the
Investor in VWAP Purchases under the Purchase Agreement) as shall be permitted to be included in such Initial Registration Statement in
accordance with applicable Commission rules, regulations and interpretations so as to permit the resale of such Registrable Securities
by the Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices) (the “Initial
Registration Statement”). The Initial Registration Statement shall contain the “Selling Stockholder” and “Plan
of Distribution” sections in substantially the form attached hereto as Exhibit B. The Company shall use its commercially
reasonable efforts to have the Initial Registration Statement declared effective by the Commission as soon as reasonably practicable,
but in no event later than the applicable Effectiveness Deadline.

 

(b)            Legal
Counsel. Subject to Section 5 hereof, the Investor shall have the right to select one legal counsel to review and oversee, solely
on its behalf, any registration pursuant to this Section 2 (“Legal Counsel”), which shall be Dorsey &
Whitney LLP, or such other counsel as thereafter designated by the Investor. Except as provided under Section 10.1(i) of the
Purchase Agreement, the Company shall have no obligation to reimburse the Investor for any and all legal fees and expenses of the Legal
Counsel incurred in connection with the transactions contemplated hereby.

 

(c)            Sufficient
Number of Shares Registered. If at any time all Registrable Securities are not covered by the Initial Registration Statement filed
pursuant to Section 2(a) as a result of Section 2(e) or otherwise, the Company shall use its commercially reasonable
efforts to file with the Commission one or more additional Registration Statements so as to cover all of the Registrable Securities not
covered by the Initial Registration Statement, in each case, as soon as practicable (taking into account any position of the staff of
the Commission (“Staff”) with respect to the date on which the Staff will permit such additional Registration
Statement(s) to be filed with the Commission and the rules and regulations of the Commission) (each such additional Registration
Statement, a “New Registration Statement”), but in no event later than the applicable Filing Deadline for such
New Registration Statement(s). The Company shall use its commercially reasonable efforts to cause each such New Registration Statement
to become effective as soon as practicable following the filing thereof with the Commission, but in no event later than the applicable
Effectiveness Deadline for such New Registration Statement.

 

    4 

     

    

 

(d)            No
Inclusion of Other Securities. In no event shall the Company include any securities other than Registrable Securities on any Registration
Statement pursuant to Section 2(a) or Section 2(c) without consulting the Investor and Legal Counsel prior to filing
such Registration Statement with the Commission.

 

(e)           Offering.
If the Staff or the Commission seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement
as constituting an offering of securities that does not permit such Registration Statement to become effective and be used for resales
by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices), or if after
the filing of any Registration Statement pursuant to Section 2(a) or Section 2(c), the Company is otherwise required by
the Staff or the Commission to reduce the number of Registrable Securities included in such Registration Statement, then the Company shall
reduce the number of Registrable Securities to be included in such Registration Statement (after consultation with the Investor and Legal
Counsel as to the specific Registrable Securities to be removed therefrom) until such time as the Staff and the Commission shall so permit
such Registration Statement to become effective and be used as aforesaid. Notwithstanding anything in this Agreement to the contrary,
if after giving effect to the actions referred to in the immediately preceding sentence, the Staff or the Commission does not permit such
Registration Statement to become effective and be used for resales by the Investor on a delayed or continuous basis under Rule 415
at then-prevailing market prices (and not fixed prices), the Company shall not request acceleration of the Effective Date of such Registration
Statement, the Company shall promptly (but in no event later than 48 hours) request the withdrawal of such Registration Statement pursuant
to Rule 477 under the Securities Act, and the Effectiveness Deadline shall automatically be deemed to have elapsed with respect to
such Registration Statement at such time as the Staff or the Commission has made a final and non-appealable determination that the Commission
will not permit such Registration Statement to be so utilized (unless prior to such time the Company has received assurances from the
Staff or the Commission that a New Registration Statement filed by the Company with the Commission promptly thereafter may be so utilized).
In the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall use its commercially reasonable
efforts to file one or more New Registration Statements with the Commission in accordance with Section 2(c) until such time
as all Registrable Securities have been included in Registration Statements that have been declared effective and the Prospectuses contained
therein are available for use by the Investor.

 

(f)            Any
Registrable Security shall cease to be a “Registrable Security” at the earliest of the following: (i) when a Registration
Statement covering such Registrable Security becomes or has been declared effective by the Commission and such Registrable Security has
been sold or disposed of pursuant to such effective Registration Statement; (ii) when such Registrable Security is held by the Company
or one of its Subsidiaries; and (iii) the date that is the later of (A) the first (1st) anniversary of the date of
termination of the Purchase Agreement in accordance with Article VIII of the Purchase Agreement and (B) the first (1st)
anniversary of the date of the last sale of any Registrable Securities to the Investor pursuant to the Purchase Agreement.

 

    5 

     

    

 

		3.	Related Obligations.

 

The Company shall use its
commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition
thereof, and, pursuant thereto, during the term of this Agreement, the Company shall have the following obligations:

 

(a)            The
Company shall promptly prepare and file with the Commission the Initial Registration Statement pursuant to Section 2(a) hereof
and one or more New Registration Statements pursuant to Section 2(c) hereof with respect to the Registrable Securities, but
in no event later than the applicable Filing Deadline therefor, and the Company use its commercially reasonable efforts to cause each
such Registration Statement to become effective as soon as practicable after such filing, but in no event later than the applicable Effectiveness
Deadline therefor. Subject to Allowable Grace Periods, the Company shall keep each Registration Statement effective (and the Prospectus
contained therein available for use) pursuant to Rule 415 for resales by the Investor on a continuous basis at then-prevailing market
prices (and not fixed prices) at all times until the earlier of (i) the date on which the Investor shall have sold all of the Registrable
Securities covered by such Registration Statement and (ii) the date of termination of the Purchase Agreement if as of such termination
date the Investor holds no Registrable Securities (or, if applicable, the date on which such securities cease to be Registrable Securities
after the date of termination of the Purchase Agreement) (the “Registration Period”). Notwithstanding anything
to the contrary contained in this Agreement (but subject to the provisions of Section 3(q) hereof), the Company shall ensure
that, when filed and at all times while effective, each Registration Statement (including, without limitation, all amendments and supplements
thereto) and the Prospectus (including, without limitation, all amendments and supplements thereto) used in connection with such Registration
Statement shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or
necessary to make the statements therein (in the case of Prospectuses, in the light of the circumstances in which they were made) not
misleading. The Company shall submit to the Commission, as soon as reasonably practicable after the date that the Company learns that
no review of a particular Registration Statement will be made by the Staff or that the Staff has no further comments on a particular Registration
Statement (as the case may be), a request for acceleration of effectiveness of such Registration Statement to a time and date as soon
as reasonably practicable in accordance with Rule 461 under the Securities Act.

 

    6 

     

    

 

(b)            Subject
to Section 3(q) of this Agreement, the Company shall use its commercially reasonable efforts to prepare and file with the Commission
such amendments (including, without limitation, post-effective amendments) and supplements to each Registration Statement and the Prospectus
used in connection with each such Registration Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under
the Securities Act, as may be necessary to keep each such Registration Statement effective (and the Prospectus contained therein current
and available for use) at all times during the Registration Period for such Registration Statement, and, during such period, comply with
the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company required to be covered
by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with the
intended methods of disposition by the Investor. Without limiting the generality of the foregoing, the Company covenants and agrees that
(i) at or before 8:30 a.m. (New York City time) on the Trading Day immediately following the Effective Date of the Initial Registration
Statement and any New Registration Statement (or any post-effective amendment thereto), the Company shall file with the Commission in
accordance with Rule 424(b) under the Securities Act the final Prospectus to be used in connection with sales pursuant to such
Registration Statement (or post-effective amendment thereto), and (ii) if the transactions contemplated by any VWAP Purchase are
material to the Company (individually or collectively with all other prior VWAP Purchases, the consummation of which have not previously
been reported in any Prospectus Supplement filed with the Commission under Rule 424(b) under the Securities Act or in any report,
statement or other document filed by the Company with the Commission under the Exchange Act), or if otherwise required under the Securities
Act (or the interpretations of the Commission thereof), in each case as reasonably determined by the Company and the Investor, then, at
or before 8:30 a.m., New York City time, on the first (1st) Trading Day immediately following the VWAP Purchase Date, if a
VWAP Purchase Notice was properly delivered to the Investor hereunder in connection with such VWAP Purchase, the Company shall file with
the Commission a Prospectus Supplement pursuant to Rule 424(b) under the Securities Act with respect to the VWAP Purchase(s),
the total VWAP Purchase Price for the Shares subject to such VWAP Purchase(s) (as applicable), the applicable VWAP Purchase Price(s) for
such Shares and the net proceeds that are to be (and, if applicable, have been) received by the Company from the sale of such Shares.
To the extent not previously disclosed in the Prospectus or a Prospectus Supplement, the Company shall disclose in its Quarterly Reports
on Form 10-Q and in its Annual Reports on Form 10-K the information described in the immediately preceding sentence relating
to all VWAP Purchase(s) consummated during the relevant fiscal quarter and shall file such Quarterly Reports and Annual Reports with
the Commission within the applicable time period prescribed for such report under the Exchange Act. In the case of amendments and supplements
to any Registration Statement on Form S-1 or Prospectus related thereto which are required to be filed pursuant to this Agreement
(including, without limitation, pursuant to this Section 3(b)) by reason of the Company filing a report on Form 8-K, Form 10-Q
or Form 10-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such
Registration Statement and Prospectus, if applicable, or shall file such amendments or supplements to the Registration Statement or Prospectus
with the Commission on the same day on which the Exchange Act report is filed which created the requirement for the Company to amend or
supplement such Registration Statement or Prospectus, for the purpose of including or incorporating such report into such Registration
Statement and Prospectus. The Company consents to the use of the Prospectus (including, without limitation, any supplement thereto) included
in each Registration Statement in accordance with the provisions of the Securities Act and with the securities or “Blue Sky”
laws of the jurisdictions in which the Registrable Securities may be sold by the Investor, in connection with the resale of the Registrable
Securities and for such period of time thereafter as such Prospectus (including, without limitation, any supplement thereto) (or in lieu
thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities Act to be delivered in
connection with resales of Registrable Securities.

 

    7 

     

    

 

(c)            The
Company shall (A) permit Legal Counsel an opportunity to review and comment upon (i) each Registration Statement at least two
(2) Business Days prior to its filing with the Commission and (ii) all amendments and supplements to each Registration Statement
(including, without limitation, the Prospectus contained therein) (except for Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and any similar or successor reports or Prospectus Supplements the contents of which is limited to that
set forth in such reports) within a reasonable number of days prior to their filing with the Commission, and (B) shall reasonably
consider any comments of the Investor and Legal Counsel on any such Registration Statement or amendment or supplement thereto or to any
Prospectus contained therein. The Company shall promptly furnish to Legal Counsel, without charge, (i) electronic copies of any correspondence
from the Commission or the Staff to the Company or its representatives relating to each Registration Statement (which correspondence shall
be redacted to exclude any material, non-public information regarding the Company or any of its Subsidiaries), (ii) after the same
is prepared and filed with the Commission, one (1) electronic copy of each Registration Statement and any amendment(s) and supplement(s) thereto,
including, without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by the
Investor, and all exhibits and (iii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus
included in such Registration Statement and all amendments and supplements thereto; provided, however, the Company shall not be required
to furnish any document (other than the Prospectus, which may be provided in .PDF format) to Legal Counsel to the extent such document
is available on EDGAR).

  

(d)            Without
limiting any obligation of the Company under the Purchase Agreement, the Company shall promptly furnish to the Investor, without charge,
(i) after the same is prepared and filed with the Commission, at least one (1) electronic copy of each Registration Statement
and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents
incorporated therein by reference, if requested by the Investor, all exhibits thereto, (ii) upon the effectiveness of each Registration
Statement, one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and supplements thereto
(or such other number of copies as the Investor may reasonably request from time to time) and (iii) such other documents, including,
without limitation, copies of any final Prospectus and any Prospectus Supplement thereto, as the Investor may reasonably request from
time to time in order to facilitate the disposition of the Registrable Securities owned by the Investor; provided, however, the Company
shall not be required to furnish any document (other than the Prospectus, which may be provided in .PDF format) to the Investor to the
extent such document is available on EDGAR).

 

(e)            The
Company shall take such action as is reasonably necessary to (i) register and qualify, unless an exemption from registration and
qualification applies, the resale by the Investor of the Registrable Securities covered by a Registration Statement under such other securities
or “Blue Sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions,
such amendments (including, without limitation, post-effective amendments) and supplements to such registrations and qualifications as
may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably
necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take
all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided,
however, the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business
in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(e), (y) subject itself to general
taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction. The Company shall
promptly notify Legal Counsel and the Investor of the receipt by the Company of any notification with respect to the suspension of the
registration or qualification of any of the Registrable Securities for sale under the securities or “Blue Sky” laws of any
jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.

 

    8 

     

    

 

(f)            The
Company shall notify Legal Counsel and the Investor in writing of the happening of any event, as promptly as reasonably practicable after
becoming aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an
untrue statement of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain
any material, non-public information regarding the Company or any of its Subsidiaries), and, subject to Section 3(q), promptly prepare
a supplement or amendment to such Registration Statement and such Prospectus contained therein to correct such untrue statement or omission
and deliver one (1) electronic copy of such supplement or amendment to Legal Counsel and the Investor (or such other number of copies
as Legal Counsel or the Investor may reasonably request). The Company shall also promptly notify Legal Counsel and the Investor in writing
(i) when a Prospectus or any Prospectus Supplement or post-effective amendment has been filed, when a Registration Statement or any
post-effective amendment has become effective (notification of such effectiveness shall be delivered to Legal Counsel and the Investor
by facsimile or e-mail on the same day of such effectiveness and by overnight mail), and when the Company receives written notice from
the Commission that a Registration Statement or any post-effective amendment will be reviewed by the Commission, (ii) of any request
by the Commission for amendments or supplements to a Registration Statement or related Prospectus or related information, (iii) of
the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate and (iv) of
the receipt of any request by the Commission or any other federal or state governmental authority for any additional information relating
to the Registration Statement or any amendment or supplement thereto or any related Prospectus. The Company shall respond as promptly
as reasonably practicable to any comments received from the Commission with respect to a Registration Statement or any amendment thereto.
Nothing in this Section 3(f) shall limit any obligation of the Company under the Purchase Agreement.

 

(g)            The
Company shall (i) use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of a Registration Statement or the use of any Prospectus contained therein, or the suspension of the qualification, or the loss of an
exemption from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is
issued, to obtain the withdrawal of such order or suspension at the earliest possible time and (ii) notify Legal Counsel and the
Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.

 

(h)            The
Company shall hold in confidence and not make any disclosure of information concerning the Investor provided to the Company unless (i) disclosure
of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary
to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in such Registration
Statement pursuant to the Securities Act, (iii) the release of such information is ordered pursuant to a subpoena or other final,
non-appealable order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally
available to the public other than by disclosure in violation of this Agreement or any other Transaction Document. The Company agrees
that it shall, upon learning that disclosure of such information concerning the Investor is sought in or by a court or governmental body
of competent jurisdiction or through other means, give prompt written notice to the Investor and allow the Investor, at the Investor’s
expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

    9 

     

    

 

(i)            Without
limiting any obligation of the Company under the Purchase Agreement, the Company shall use its commercially reasonable efforts either
to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on the Trading Market, or (ii) secure
designation and quotation of all of the Registrable Securities covered by each Registration Statement on another Eligible Market. In addition,
the Company shall reasonably cooperate with the Investor and any Broker-Dealer through which the Investor proposes to sell its Registrable
Securities in effecting a filing with the Financial Industry Regulatory Authority, Inc. (“FINRA”) pursuant
to FINRA Rule 5110 as requested by the Investor. The Company shall pay all fees and expenses in connection with satisfying its obligation
under this Section 3(i).

 

(j)            The
Company shall cooperate with the Investor and, to the extent applicable, facilitate the timely preparation and delivery of Registrable
Securities, as DWAC Shares, to be offered pursuant to a Registration Statement and enable such DWAC Shares to be in such denominations
or amounts (as the case may be) as the Investor may reasonably request from time to time and registered in such names as the Investor
may request. Investor hereby agrees that it shall cooperate with the Company, its counsel and its transfer agent in connection with any
issuances of DWAC Shares, and hereby represents, warrants and covenants to the Company that that it will resell such DWAC Shares only
pursuant to the Registration Statement in which such DWAC Shares are included, in a manner described under the caption “Plan of
Distribution” in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities
laws, rules and regulations, including, without limitation, any applicable prospectus delivery requirements of the Securities Act.
DWAC Shares shall be free from all restrictive legends may be transmitted by the transfer agent to the Investor by crediting an account
at DTC as directed in writing by the Investor.

 

(k)            Upon
the written request of the Investor, the Company shall as soon as reasonably practicable after receipt of notice from the Investor and
subject to Section 3(p) hereof, (i) incorporate in a Prospectus Supplement or post-effective amendment such information
as the Investor reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including,
without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid
therefor and any other terms of the offering of the Registrable Securities to be sold in such offering; (ii) make all required filings
of such Prospectus Supplement or post-effective amendment after being notified of the matters to be incorporated in such Prospectus Supplement
or post-effective amendment; and (iii) supplement or make amendments to any Registration Statement or Prospectus contained therein
if reasonably requested by the Investor.

 

    10 

     

    

 

(l)           The
Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by a Registration Statement to be registered
with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities.

  

(m)         The
Company shall make generally available to its security holders (which may be satisfied by making such information available on EDGAR)
as soon as practical, but not later than ninety (90) days after the close of the period covered thereby, an earnings statement (in form
complying with, and in the manner provided by, the provisions of Rule 158 under the Securities Act) covering a twelve-month period
beginning not later than the first day of the Company’s fiscal quarter next following the applicable Effective Date of each Registration
Statement.

 

(n)            The
Company shall otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the Commission
in connection with any registration hereunder.

 

(o)            Within
one (1) Business Day after each Registration Statement which covers Registrable Securities is declared effective by the Commission,
the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investor) confirmation that such Registration Statement has been declared effective by the Commission in the form
attached hereto as Exhibit A.

 

(p)         Notwithstanding
anything to the contrary contained herein (but subject to the last sentence of this Section 3(p)), at any time after the Effective
Date of a particular Registration Statement, the Company may, upon written notice to Investor, suspend Investor’s use of any prospectus
that is a part of any Registration Statement (in which event the Investor shall discontinue sales of the Registrable Securities pursuant
to such Registration Statement contemplated by this Agreement, but shall settle any previously made sales of Registrable Securities) if
the Company (x) is pursuing an acquisition, merger, tender offer, reorganization, disposition or other similar transaction and the
Company determines in good faith that (A) the Company’s ability to pursue or consummate such a transaction would be materially
adversely affected by any required disclosure of such transaction in such Registration Statement or other registration statement or (B) such
transaction renders the Company unable to comply with Commission requirements, in each case under circumstances that would make it impractical
or inadvisable to cause any Registration Statement (or such filings) to be used by Investor or to promptly amend or supplement any Registration
Statement contemplated by this Agreement on a post effective basis, as applicable, or (y) has experienced some other material non-public
event the disclosure of which at such time, in the good faith judgment of the Company, would materially adversely affect the Company (each,
an “Allowable Grace Period”); provided, however, that in no event shall the Investor be suspended from
selling Registrable Securities pursuant to any Registration Statement for a period that exceeds 20 consecutive Trading Days or an aggregate
of 60 days in any 365-day period; and provided, further, the Company shall not effect any such suspension during (A) the first
10 consecutive Trading Days after the Effective Date of the particular Registration Statement, (B) the five-Trading Day period commencing
on the Commencement Date, or (C) the five-Trading Day period commencing on the VWAP Purchase Date for each VWAP Purchase. Upon disclosure
of such information or the termination of the condition described above, the Company shall provide prompt notice, but in any event within
one Business Day of such disclosure or termination, to the Investor and shall promptly terminate any suspension of sales it has put into
effect and shall take such other reasonable actions to permit registered sales of Registrable Securities as contemplated in this Agreement
(including as set forth in the first sentence of Section 3(f) with respect to the information giving rise thereto unless such
material, non-public information is no longer applicable). Notwithstanding anything to the contrary contained in this Section 3(p),
the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of the Investor in accordance with the terms of the
Purchase Agreement in connection with any sale of Registrable Securities with respect to which (i) the Company has made a sale to
Investor and (ii) the Investor has entered into a contract for sale, and delivered a copy of the Prospectus included as part of the
particular Registration Statement to the extent applicable, in each case prior to the Investor’s receipt of the notice of an Allowable
Grace Period and for which the Investor has not yet settled.

 

    11 

     

    

 

		4.	Obligations of the Investor.

 

(a)          At
least five (5) Business Days prior to the first anticipated filing date of each Registration Statement (or such shorter period to
which the parties agree), the Company shall notify the Investor in writing of the information the Company requires from the Investor with
respect to such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the registration
pursuant to this Agreement with respect to the Registrable Securities of the Investor that the Investor shall furnish to the Company such
information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities
held by it, as shall be reasonably required to effect and maintain the effectiveness of the registration of such Registrable Securities
and shall execute such documents in connection with such registration as the Company may reasonably request.

 

(b)          The
Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of each Registration Statement hereunder, unless the Investor has notified the Company in
writing of the Investor’s election to exclude all of the Investor’s Registrable Securities from such Registration Statement.

 

(c)          The
Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(p) or
the first sentence of 3(f), the Investor shall immediately discontinue disposition of Registrable Securities pursuant to any Registration
Statement(s) covering such Registrable Securities until the Investor’s receipt of the copies of the supplemented or amended
Prospectus contemplated by Section 3(p) or the first sentence of Section 3(f) or receipt of notice that no supplement
or amendment is required. Notwithstanding anything to the contrary in this Section 4(c), the Company shall cause its transfer agent
to deliver DWAC Shares to a transferee of the Investor in accordance with the terms of the Purchase Agreement in connection with any sale
of Registrable Securities with respect to which the Investor has entered into a contract for sale prior to the Investor’s receipt
of a notice from the Company of the happening of any event of the kind described in Section 3(p) or the first sentence of Section 3(f) and
for which the Investor has not yet settled.

 

    12 

     

    

 

(d)            The
Investor covenants and agrees that it shall comply with the prospectus delivery and other requirements of the Securities Act as applicable
to it in connection with sales of Registrable Securities pursuant to a Registration Statement.

 

		5.	Expenses of Registration.

 

All reasonable expenses of
the Company, other than sales or brokerage commissions and fees and disbursements of counsel for, and other expenses of, the Investor,
incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all
registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall
be paid by the Company.

 

		6.	Indemnification.

 

(a)            In
the event any Registrable Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted
by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each of its directors, officers, shareholders,
members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls the Investor within
the meaning of the Securities Act or the Exchange Act and each of the directors, officers, shareholders, members, partners, employees,
agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
the lack of such title or any other title) of such controlling Persons (each, an “Investor Party” and collectively,
the “Investor Parties”), against any losses, obligations, claims, damages, liabilities, contingencies, judgments,
fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees, costs of defense and investigation),
amounts paid in settlement or expenses, joint or several, (collectively, “Claims”) reasonably incurred in investigating,
preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any
court or governmental, administrative or other regulatory agency, body or the Commission, whether pending or threatened, whether or not
an Investor Party is or may be a party thereto (“Indemnified Damages”), to which any of them may become subject
insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon:
(i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment
thereto or in any filing made in connection with the qualification of the offering under the securities or other “Blue Sky”
laws of any jurisdiction in which Registrable Securities are offered (“Blue Sky Filing”), or the omission or
alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading or
(ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus (as amended or supplemented)
or in any Prospectus Supplement or the omission or alleged omission to state therein any material fact necessary to make the statements
made therein, in light of the circumstances under which the statements therein were made, not misleading (the matters in the foregoing
clauses (i) and (ii) being, collectively, “Violations”). Subject to Section 6(e), the Company
shall reimburse the Investor Parties, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable
expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained
herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Investor Party arising
out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company
by such Investor Party for such Investor Party expressly for use in connection with the preparation of such Registration Statement, Prospectus
or Prospectus Supplement or any such amendment thereof or supplement thereto (it being hereby acknowledged and agreed that the written
information set forth on Exhibit C attached hereto is the only written information furnished to the Company by or on behalf
of the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); (ii) shall not be available
to the Investor to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the Prospectus (as
amended or supplemented) made available by the Company (to the extent applicable), including, without limitation, a corrected Prospectus,
if such Prospectus (as amended or supplemented) or corrected Prospectus was timely made available by the Company pursuant to Section 3(d) and
then only if, and to the extent that, following the receipt of the corrected Prospectus no grounds for such Claim would have existed;
and (iii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent
of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of the Investor Party and shall survive the transfer of any of the Registrable Securities by
the Investor pursuant to Section 9.

 

    13 

     

    

 

(b)            In
connection with any Registration Statement in which the Investor is participating, the Investor agrees to severally and not jointly indemnify,
hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within the meaning of the
Securities Act or the Exchange Act (each, an “Company Party”), against any Claim or Indemnified Damages to which
any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages
arise out of or are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance
upon and in conformity with written information relating to the Investor furnished to the Company by the Investor expressly for use in
connection with such Registration Statement, the Prospectus included therein or any Prospectus Supplement thereto (it being hereby acknowledged
and agreed that the written information set forth on Exhibit C attached hereto is the only written information furnished to
the Company by or on behalf of the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); and,
subject to Section 6(e) and the below provisos in this Section 6(b), the Investor shall reimburse a Company Party any legal
or other expenses reasonably incurred by such Company Party in connection with investigating or defending any such Claim; provided,
however, the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained
in Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written
consent of the Investor, which consent shall not be unreasonably withheld or delayed; and provided, further that the Investor shall
be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds
to the Investor as a result of the applicable sale of Registrable Securities pursuant to such Registration Statement, Prospectus or Prospectus
Supplement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Company
Party and shall survive the transfer of any of the Registrable Securities by the Investor pursuant to Section 9.

 

    14 

     

    

 

(c)            Promptly
after receipt by an Investor Party or Company Party (as the case may be) under this Section 6 of notice of the commencement of any
action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Investor Party or
Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 6,
deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate
in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control
of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Investor Party or the Company Party (as the
case may be); provided, however, an Investor Party or Company Party (as the case may be) shall have the right to retain
its own counsel with the fees and expenses of such counsel to be paid by the indemnifying party if: (i) the indemnifying party has
agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have failed promptly to assume the defense of
such Claim and to employ counsel reasonably satisfactory to such Investor Party or Company Party (as the case may be) in any such Claim;
or (iii) the named parties to any such Claim (including, without limitation, any impleaded parties) include both such Investor Party
or Company Party (as the case may be) and the indemnifying party, and such Investor Party or such Company Party (as the case may be) shall
have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Investor Party
or such Company Party and the indemnifying party (in which case, if such Investor Party or such Company Party (as the case may be) notifies
the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, then the indemnifying
party shall not have the right to assume the defense thereof on behalf of the indemnified party and such counsel shall be at the expense
of the indemnifying party, provided further that in the case of clause (iii) above the indemnifying party shall not be responsible
for the reasonable fees and expenses of more than one (1) separate legal counsel for all Investor Parties or Company Parties (as
the case may be). The Company Party or Investor Party (as the case may be) shall reasonably cooperate with the indemnifying party in connection
with any negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all
information reasonably available to the Company Party or Investor Party (as the case may be) which relates to such action or Claim. The
indemnifying party shall keep the Company Party or Investor Party (as the case may be) reasonably apprised at all times as to the status
of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action,
claim or proceeding effected without its prior written consent; provided, however, the indemnifying party shall not unreasonably
withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Company Party or Investor
Party (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise which does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such Company Party or Investor Party (as the case may be) of
a release from all liability in respect to such Claim or litigation, and such settlement shall not include any admission as to fault on
the part of the Company Party. For the avoidance of doubt, the immediately preceding sentence shall apply to Sections 6(a) and 6(b) hereof.
Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Company Party or
Investor Party (as the case may be) with respect to all third parties, firms or corporations relating to the matter for which indemnification
has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such
action shall not relieve such indemnifying party of any liability to the Investor Party or Company Party (as the case may be) under this
Section 6, except to the extent that the indemnifying party is materially and adversely prejudiced in its ability to defend such
action.

 

    15 

     

    

 

(d)         No
Person involved in the sale of Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) in connection with such sale shall be entitled to indemnification from any Person involved in such sale of Registrable
Securities who is not guilty of fraudulent misrepresentation.

 

(e)        The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred; provided that any Person receiving any payment
pursuant to this Section 6 shall promptly reimburse the Person making such payment for the amount of such payment to the extent a
court of competent jurisdiction determines that such Person receiving such payment was not entitled to such payment.

 

(f)          The
indemnity and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company
Party or Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject
to pursuant to the law.

 

		7.	Contribution.

 

To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however:
(i) no contribution shall be made under circumstances where the maker would not have been liable for indemnification under the fault
standards set forth in Section 6 of this Agreement, (ii) no Person involved in the sale of Registrable Securities which Person
is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) in connection with such
sale shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent
misrepresentation; and (iii) contribution by any seller of Registrable Securities shall be limited in amount to the amount of net
proceeds received by such seller from the applicable sale of such Registrable Securities pursuant to such Registration Statement. Notwithstanding
the provisions of this Section 7, the Investor shall not be required to contribute, in the aggregate, any amount in excess of the
amount by which the net proceeds actually received by the Investor from the applicable sale of the Registrable Securities subject to the
Claim exceeds the amount of any damages that the Investor has otherwise been required to pay, or would otherwise be required to pay under
Section 6(b), by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

		8.	Reports Under the Exchange Act.

 

With a view to making available
to the Investor the benefits of Rule 144, the Company agrees to:

 

(a)            use
its reasonable best efforts to make and keep public information available, as those terms are understood and defined in Rule 144;

 

    16 

     

    

 

(b)          use
its reasonable best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act so long as the Company remains subject to such requirements (it being understood that nothing
herein shall limit any of the Company’s obligations under the Purchase Agreement) and the filing of such reports and other documents
is required for the applicable provisions of Rule 144;

 

(c)            furnish
to the Investor so long as the Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company,
if true, that it has complied with the reporting, submission and posting requirements of Rule 144 and the Exchange Act, (ii) a
copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company with the
Commission if such reports are not publicly available via EDGAR, and (iii) such other information as may be reasonably requested
to permit the Investor to sell such securities pursuant to Rule 144 without registration; and

 

(d)          take
such additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable Securities pursuant to
Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions
to the Company’s Transfer Agent as may be reasonably requested from time to time by the Investor and otherwise fully cooperate with
Investor and Investor’s broker to effect such sale of securities pursuant to Rule 144.

 

		9.	Assignment of Registration Rights.

 

Neither the Company nor the
Investor shall assign this Agreement or any of their respective rights or obligations hereunder.

 

		10.	Amendment or Waiver.

 

No
provision of this Agreement may be amended or waived by the parties from and after the date that is one (1) Trading Day immediately
preceding the date on which the Initial Registration Statement is initially filed with the Commission. Subject to the immediately
preceding sentence, no provision of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto
or (ii) waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof.

 

		11.	Miscellaneous.

 

(a)            Solely
for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to
own of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons
with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from
such record owner of such Registrable Securities.

 

(b)            Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement shall be given
in accordance with Section 10.4 of the Purchase Agreement.

 

    17 

     

    

 

(c)           Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof. The Company and the Investor acknowledge and agree that irreparable damage would occur in the event
that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It
is accordingly agreed that either party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions
of this Agreement by the other party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic
loss and without any bond or other security being required), this being in addition to any other remedy to which either party may be entitled
by law or equity.

 

(d)            All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the federal courts sitting in The City of New York, Borough of
Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision of this Agreement
shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability
of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(e)            The
Transaction Documents set forth the entire agreement and understanding of the parties solely with respect to the subject matter thereof
and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral and written, solely
with respect to such matters. There are no promises, undertakings, representations or warranties by either party relative to subject matter
hereof not expressly set forth in the Transaction Documents. Notwithstanding anything in this Agreement to the contrary and without implication
that the contrary would otherwise be true, nothing contained in this Agreement shall limit, modify or affect in any manner whatsoever
(i) the conditions precedent to a VWAP Purchase contained in Article VII of the Purchase Agreement or (ii) any of the Company’s
obligations under the Purchase Agreement.

 

(f)            This
Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors. This Agreement is not
for the benefit of, nor may any provision hereof be enforced by, any Person, other than the parties hereto, their respective successors
and the Persons referred to in Sections 6 and 7 hereof.

 

    18 

     

    

 

(g)           The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless the
context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural
forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed
broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof”
and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

(h)           This
Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature
or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding
upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

(i)            Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents as any other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(j)            The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of
strict construction will be applied against any party.

 

[Signature Pages Follow]

 

    19 

     

    

 

IN
WITNESS WHEREOF, Investor and the Company have caused their respective signature page to this Registration Rights
Agreement to be duly executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	BIOHITECH GLOBAL, INC.
	 	 
	 	By:	 
	 	Name:
	 	Title:

 

    20 

     

    

 

IN
WITNESS WHEREOF, Investor and the Company have caused their respective signature page to this Registration Rights
Agreement to be duly executed as of the date first written above.

  

	 	INVESTOR:
	 	 
	 	KEYSTONE CAPITAL PARTNERS, LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:

 

    21 

     

    

 

 

EXHIBIT A

 

FORM OF
NOTICE OF EFFECTIVENESS

OF REGISTRATION STATEMENT

 

[●]

[●]

[●]

 

	Re:	BioHiTech Global, Inc.

 

Ladies and Gentlemen:

 

We
are counsel to BioHiTech Global, Inc., a Delaware corporation (the “Company”), and have represented
the Company in connection with that certain Common Stock Purchase Agreement, dated September 23, 2021 (the “Purchase
Agreement”), entered into by and among the Company and the Investor named therein (the “Holder”)
pursuant to which the Company has issued and will issue to the Holder from time to time shares of the Company’s common stock, par
value $0.0001 per share (the ”Common Stock”). Pursuant to the Purchase Agreement, the Company also has
entered into a Registration Rights Agreement, dated September 23, 2021, with the Holder (the “Registration Rights Agreement”),
pursuant to which the Company agreed, among other things, to register the offer and sale by the Holder of the Registrable Securities (as
defined in the Registration Rights Agreement) under the Securities Act of 1933, as amended (the “Securities Act”).
In connection with the Company’s obligations under the Registration Rights Agreement, on [●], 202[●], the Company filed
a Registration Statement on Form S-1 (File No. 333-[●]) (the “Registration Statement”) with
the Securities and Exchange Commission (the “Commission”) relating to the Registrable Securities which names
the Holder as an underwriter and a selling stockholder thereunder.

 

In
connection with the foregoing, based solely on our review of the Commission’s EDGAR website, we advise you that the Registration
Statement became effective under the Securities Act on [●], 202[●]. In addition, based solely on our review of the information
made available by the Commission at http://www.sec.gov/litigation/stoporders.shtml, we confirm that the Commission has not issued any
stop order suspending the effectiveness of the Registration Statement. To our knowledge, based solely on our participation in the conferences
mentioned above regarding the Registration Statement and our review of the information made available by the Commission at http://www.sec.gov/litigation/stoporders.shtml,
no proceedings for that purpose are pending or have been instituted or threatened by the Commission.

 

This letter shall serve as
our standing opinion to you that the shares of Common Stock are freely transferable by the Holder pursuant to the Registration Statement,
provided the Registration Statement remains effective.

 

This opinion letter is limited
to the federal securities laws of the United States of America. We express no opinion as to matters relating to state securities laws
or Blue Sky laws.

 

     

     

    

 

We assume no obligation to
update or supplement this opinion letter to reflect any facts or circumstances which may hereafter come to our attention with respect
to the opinion and statements expressed above, including any changes in applicable law that may hereafter occur.

 

This opinion letter is being
delivered solely for the benefit of the person to whom it is addressed; accordingly, it may not be quoted, filed with any governmental
authority or other regulatory agency or otherwise circulated or utilized for any purposes without our prior written consent.

 

	 	Very truly yours,

 

	 	[ISSUER’S COUNSEL]

 

		By:	

 

cc: Keystone Capital Partners, LLC

 

     

     

    

 

EXHIBIT B

 

SELLING
STOCKHOLDER

 

This
prospectus relates to the offer and sale by Keystone Capital Partners of up to [●] shares of common stock that have been
and may be issued by us to Keystone Capital Partners under the Purchase Agreement. For additional information regarding the shares of
common stock included in this prospectus, see the section titled “Committed Equity Financing” above. We are registering the
shares of common stock included in this prospectus pursuant to the provisions of the Registration Rights Agreement we entered into with
Keystone Capital Partners on September 23, 2021 in order to permit the selling stockholder to offer the shares for resale from time
to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement, Keystone Capital Partners
has not had any material relationship with us within the past three years. As used in this prospectus, the term “selling stockholder”
means Keystone Capital Partners, LLC.

 

The
table below presents information regarding the selling stockholder and the shares of common stock that may be resold by the selling stockholder
from time to time under this prospectus. This table is prepared based on information supplied to us by the selling stockholder, and reflects
holdings as of [●], 2021. The number of shares in the column “Maximum Number of Shares of Common Stock to be Offered
Pursuant to this Prospectus” represents all of the shares of common stock being offered for resale by the selling stockholder under
this prospectus. The selling stockholder may sell some, all or none of the shares being offered for resale in this offering. We do not
know how long the selling stockholder will hold the shares before selling them, and we know of no existing arrangements between the selling
stockholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our common
stock offered by this prospectus.

 

Beneficial
ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes
shares of common stock with respect to which the selling stockholder has voting power, including the power to vote or to direct the voting
of such shares, and/or investment power, including the power to dispose or to direct the disposition of such shares. The percentage of
shares of common stock beneficially owned by the selling stockholder prior to the offering shown in the table below is based on an aggregate
of [●] shares of our common stock outstanding on [●], 2021.

 

Because
the purchase price per share to be paid by the selling stockholder for the shares of common stock that we may, in our discretion, elect
to sell to the selling stockholder from time to time after the date of this prospectus in VWAP Purchases pursuant to the Purchase Agreement,
if any, will fluctuate based on the market prices of our common stock at the times we elect to sell such shares to the selling stockholder
in VWAP Purchases under the Purchase Agreement, aside from the 625,000 Initial Purchase Shares we sold to the selling stockholder for
an aggregate gross purchase price of $750,000 in an initial purchase under the Purchase Agreement on September 23, 2021, it is not
possible for us to predict, as of the date of this prospectus and prior to any such VWAP Purchases under the Purchase Agreement, the actual
number of shares of common stock that we will sell to the selling stockholder under the Purchase Agreement, which may be fewer
than the number of shares of common stock being offered for resale by the selling stockholder under this prospectus. The fourth column
assumes the resale by the selling stockholder of all of the shares of common stock being offered pursuant to this prospectus.

 

     

     

    

 

	Name
of Selling Stockholder
	 	Number
    of Shares of 
 Common Stock Owned
 Prior to Offering	 	 	Maximum
    Number of 
 Shares of Common Stock
 to be Offered Pursuant to
 this Prospectus	 	 	Number
    of Shares of 

    Common Stock Owned 

    After Offering	 
	 	 	Number(1)	 	 	Percent(2)	 	 	 	 	 	Number(3)	 	 	Percent(2)	 
	Keystone Capital Partners, LLC(4)	 	 	694,137	 	 	 	*	 	 	 	[●]	 	 	 	0	 	 	 	--	 

  

* Represents
beneficial ownership of less than 1% of the outstanding shares of our common stock.

 

		(1)	This number consists of (i) the
69,137 Initial Commitment Shares we issued to the selling stockholder on September 23, 2021 in consideration for its commitment to
purchase shares of our common stock from time to time at our direction pursuant to the Purchase Agreement, and (ii) the 625,000 Initial
Purchase Shares we sold to the selling stockholder for an aggregate gross purchase price of $750,000 in an initial purchase under the
Purchase Agreement on September 23, 2021. In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from
the number of shares beneficially owned prior to the offering (i) all of the Additional Commitment Shares, because the issuance of
such Additional Commitment Shares is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely
outside of the selling stockholder’s control, and (ii) all of the shares that the selling stockholder may be required to purchase
from us at our election from time to time after the date of this prospectus pursuant to VWAP Purchases under the Purchase Agreement, because
the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction
of which are entirely outside of the selling stockholder’s control, including the registration statement that includes this prospectus
becoming and remaining effective. Furthermore, the VWAP Purchases of common stock are subject to certain agreed upon maximum amount limitations
set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any
shares of our common stock to the selling stockholder to the extent such shares, when aggregated with all other shares of our common stock
then beneficially owned by the selling stockholder, would cause the selling
stockholder’s beneficial ownership of common stock to exceed the 4.99% Beneficial Ownership Limitation. The Purchase Agreement also
prohibits us from issuing or selling shares of our common stock under the Purchase Agreement in excess of the 19.99% Exchange Cap, unless
we obtain stockholder approval to do so, or unless sales of common stock are made at a price equal to or greater than $[●]
per share, such that the Exchange Cap limitation would not apply under applicable Nasdaq rules. Neither the Beneficial Ownership Limitation
nor the Exchange Cap (to the extent applicable under Nasdaq rules) may be amended or waived under the Purchase Agreement.

 

		(2)	Applicable percentage ownership is based on [●] shares of our common stock outstanding as of [●],
2021.

 

		(3)	Assumes the sale of all shares being offered pursuant to this prospectus.

 

		(4)	The business address of Keystone Capital Partners, LLC is 139 Fulton Street, Suite 412, New York,
NY 10038. Keystone Capital Partners, LLC’s principal business is that of a private investor. Ranz Group, LLC, a Delaware limited
liability company, is the managing member of Keystone Capital Partners, LLC and the beneficial owner of 97% of the membership interests
in Keystone Capital Partners, LLC. Fredric G. Zaino is the managing member of Ranz Group, LLC and has sole voting control and investment
discretion over securities beneficially owned directly by Keystone Capital, LLC and indirectly by Ranz Group, LLC. We have been advised
that none of Mr. Zaino, Ranz Group, LLC or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory Authority,
or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing
should not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities beneficially owned
directly by Keystone Capital Partners, LLC and indirectly by Ranz Group, LLC.

 

     

     

    

 

PLAN
OF DISTRIBUTION

 

The shares of common stock
offered by this prospectus are being offered by the selling stockholder, Keystone Capital Partners, LLC.  The shares may be sold
or distributed from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters
who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated
prices, or at fixed prices, which may be changed. The sale of the shares of our common stock offered by this prospectus could be effected
in one or more of the following methods:

 

		·	ordinary brokers’ transactions;

 

		·	transactions involving cross or block trades;

 

		·	through brokers, dealers, or underwriters who may act solely as agents;

 

		·	“at the market” into an existing market for our common stock;

 

		·	in other ways not involving market makers or established business markets, including direct sales to purchasers
or sales effected through agents;

 

		·	in privately negotiated transactions; or

 

		·	any combination of the foregoing.

 

In order to comply with the
securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition,
in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from
the state’s registration or qualification requirement is available and complied with.

 

Keystone Capital Partners
is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act.

 

Keystone Capital Partners
has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our common stock that
it has acquired and may in the future acquire from us pursuant to the Purchase Agreement.  Such sales will be made at prices and
at terms then prevailing or at prices related to the then current market price.  Each such registered broker-dealer will be an underwriter
within the meaning of Section 2(a)(11) of the Securities Act.  Keystone Capital Partners has informed us that each such broker-dealer
will receive commissions from Keystone Capital Partners that will not exceed customary brokerage commissions.

 

Brokers, dealers, underwriters
or agents participating in the distribution of the shares of our common stock offered by this prospectus may receive compensation in the
form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by
the selling stockholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of
shares of our common stock sold by the selling stockholder may be less than or in excess of customary commissions.  Neither we nor
the selling stockholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of
our common stock sold by the selling stockholder.

 

     

     

    

 

We know of no existing arrangements
between the selling stockholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of
the shares of our common stock offered by this prospectus.

 

We may from time to time file
with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part
to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to
disclose certain information relating to a particular sale of shares offered by this prospectus by the selling stockholder, including
the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the selling stockholder,
any compensation paid by the selling stockholder to any such brokers, dealers, underwriters or agents, and any other required information.

 

We
will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our common stock covered
by this prospectus by the selling stockholder. As consideration for its irrevocable commitment to purchase our common stock under
the Purchase Agreement, (i) we have issued to Keystone Capital Partners 69,137 shares of our common stock as Initial Commitment Shares
upon execution of the Purchase Agreement and (ii) upon our receipt from Keystone Capital Partners of an aggregate cash amount equal
to $10,000,000 for all prior VWAP Purchases under the Purchase Agreement, we will issue to Keystone Capital Partners a number of Additional
Commitment Shares equal to the quotient obtained by dividing (a) $100,000 by (b) the arithmetic average of the volume weighted
average prices of the Common Stock for the ten consecutive trading day period including the date on which we have received $10,000,000
aggregate cash proceeds from Keystone Capital Partners under the Purchase Agreement, provided that we shall not be required to issue more
than 200,000 Additional Commitment Shares. We also have agreed to reimburse Keystone Capital Partners for the fees and disbursements of
its counsel, payable upon execution of the Purchase Agreement, in an amount not to exceed $50,000.

 

We
also have agreed to indemnify Keystone Capital Partners and certain other persons against certain liabilities in connection with
the offering of shares of our common stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity
is unavailable, to contribute amounts required to be paid in respect of such liabilities.  Keystone Capital Partners has agreed to
indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Keystone
Capital Partners specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid
in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors,
officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as
expressed in the Securities Act and is therefore, unenforceable.

 

We estimate that the total
expenses for the offering will be approximately $[●].

 

     

     

    

 

Keystone Capital Partners
has represented to us that at no time prior to the date of the Purchase Agreement has Keystone Capital Partners or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200
of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect
to our common stock.  Keystone Capital Partners has agreed that during the term of the Purchase Agreement, neither Keystone Capital
Partners, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing
transactions.

 

We have advised the selling
stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered
by this prospectus.

 

This offering will terminate
on the date that all shares of our common stock offered by this prospectus have been sold by the selling stockholder.

 

Our common stock is currently
listed on The Nasdaq Capital Market under the symbol “BHTG”.

 

     

     

    

 

EXHIBIT C

 

The business address of Keystone Capital Partners,
LLC is 139 Fulton Street, Suite 412, New York, NY 10038. Keystone Capital Partners, LLC’s principal business is that of a private
investor. Ranz Group, LLC, a Delaware limited liability company, is the managing member of Keystone Capital Partners, LLC and the beneficial
owner of 97% of the membership interests in Keystone Capital Partners, LLC. Fredric G. Zaino is the managing member of Ranz Group, LLC
and has sole voting control and investment discretion over securities beneficially owned directly by Keystone Capital, LLC and indirectly
by Ranz Group, LLC. None of Mr. Zaino, Ranz Group, LLC or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory
Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer.
The foregoing should not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities
beneficially owned directly by Keystone Capital Partners, LLC and indirectly by Ranz Group, LLC.Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (the “Agreement”)
is made and entered into as of September 23, 2021, by and between China Green Agriculture Inc., a Nevada corporation (the “Company”),
having its principal place of business at 3rd Floor, Borough A, Block A. No.181, South Taibai Road, Xi’an, Shaanxi
Province, People’s Republic of China 710065, and Xiaolai Li (the “Executive”). The Company and the Executive may be
referred to herein individually as a “Party” and collectively as the “Parties.”

 

WITNESSETH:

 

WHEREAS, the Company desires
to retain the services of Executive as the Chief Strategy Officer (the “CSO”) of the Company; and

 

WHEREAS, Executive has represented
that he has the experience, background and expertise necessary to enable him to be the Company’s CSO; and

 

WHEREAS, based on such representation,
and the Company’s reasonable due diligence, the Company wishes to employ Executive as its CSO, and Executive wishes to be so employed,
in each case, upon the terms hereinafter set forth.

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants and agreements herein contained, and other good and valuable consideration, the Parties
agree as follows:

 

1.
DEFINITIONS. As used herein, the following terms shall have the following meanings:

 

1.1 “Affiliate”
means any Person controlling, controlled by or under common control with the Company.

 

1.2 “Board”
means the Board of Directors of the Company.

 

1.3 “Common Stock”
means the Company’s $.001 par value per share common stock.

 

1.4 “Cause”
means (i) conviction of any crime whether or not committed in the course of his employment by the Company; (ii) Executive’s refusal
to carry out instructions of the Chief Executive Officer(s) or the Board which are consistent with Executive’s role as CSO; or (iii)
the breach of any representation, warranty or agreement between Executive and Company.

 

1.5 “Date of Termination”
means (a) in the case of a termination for which a Notice of Termination (as hereinafter defined in Section 5.3) is required, 30 days
from the date of actual receipt of such Notice of Termination or, if later, the date specified therein, as the case may be, and (b) in
all other cases, the actual date on which the Executive’s employment terminates during the Term of Employment (as hereinafter defined
in Section 3) (it being understood that nothing contained in this definition of “Date of Termination” shall affect any of
the cure rights provided to the Executive or the Company in this Agreement).

 

1.6 “Disability”
means Executive’s inability to render, for a period of three consecutive months, services hereunder due to his physical or mental
incapacity.

 

1.7 “Effective Date”
means September 23, 2021.

 

1.8 “Person(s)”
means any individual or entity of any kind or nature, including any other person as defined in Section 3(a)(9) of the Securities Exchange
Act of 1934, and as used in Sections 13(d) and 14(d) thereof.

 

1.9 “Prospective Customer”
shall mean any Person which has either (a) entered into a nondisclosure agreement with the Company or any Company subsidiary or Affiliate
or (b) has within the preceding 12 months received a currently pending and not rejected written proposal in reasonable detail from the
Company or any of the Company’s subsidiary or Affiliate.

 

    

     

    

 

2.
EMPLOYMENT.

 

2.1 Agreement to Employ.
As of the Effective Date, Executive agrees to be employed by the Company in the position of CSO. Executive shall report to the Board of
the Company, including any designated committee thereof. In his capacity as the CSO of the Company, Executive shall undertake the duties
and responsibilities customary to that position, subject in all instances to the direction and oversight of the Board. Executive understands
and agrees that the Board may prescribe such duties, responsibilities, and powers to each Executive Officer as it reasonably determines
appropriate, and that, in its sole discretion, the Board may revise or otherwise amend from time to time each Executive Officer’s
prescribed duties and responsibilities, provided that such duties shall at all times be limited to those customarily undertaken by a person
in such position.

 

2.2 Duties and Schedule.
Executive shall serve as the Company’s CSO and shall have such responsibilities as designated by the Company’s Board that
are not inconsistent with applicable laws, regulations and rules. Executive shall report directly to the Company’s Board, or any
designated Committee thereof, as circumstances may require.

 

3. TERM
OF EMPLOYMENT. Unless Executive’s employment shall sooner terminate pursuant to Section 5, the Company shall employ Executive
for a term commencing on the Effective Date and ending on the first anniversary thereof (the “Term”). The term shall
automatically renew for an additional year unless either Party provides notice to the other that the Term shall not continue within 60
days prior to the end of the prior Term. The period during which Executive is employed pursuant to this Agreement shall be referred to
as the “Term” or the “Term of Employment”.

 

4.
COMPENSATION.

 

4.1 Salary. Executive’s
salary during the Term shall be $300,000 per year (the “Salary”), payable in twice-monthly payments and in US Dollars.
All applicable withholding taxes shall be deducted from such payments. The Board will review Executive’s Salary at least once per
year and may, in its discretion, increase or decrease the Salary in accordance with the Company’s compensation policies. A discretionary
bonus, if any, may be paid each year as determined solely by the Board.

 

4.2 Vacation. Executive
shall be entitled to fifteen (15) days of paid vacation per year taken at such times so as to not materially impede his duties hereunder.
Executive shall be entitled to a pro rata number of days of paid vacation during the period beginning on the Effective
Date through the end of the first fiscal year. Vacation days that are not taken may not be carried over into future years. Illness days
shall be consistent with the Company’s standard policies and applicable U.S. law. Executive should be entitled to standard U.S.
federal government holidays in addition to vacation or illness days.

 

4.3 Business Expenses.
Executive shall be reimbursed by the Company for all ordinary and necessary expenses incurred by Executive in the performance of his duties
hereunder on behalf of the Company, such expenses not to exceed $500 per month without the prior written approval of the Company.

 

4.4 Section 409A Compliance.
The Executive and the Company intend that any compensation under this Agreement shall be paid in compliance with Section 409A of the Internal
Revenue Code such that there are no adverse tax consequences, interest, or penalties as a result of the payments. Notwithstanding any
other provisions of this Agreement to the contrary, any payment or benefits otherwise due to the Executive upon the Executive’s
termination from employment with the Company shall not be made until and unless such termination from employment constitutes a “Separation
from Service”, as such term is defined under Section 409A of the Internal Revenue Code. This provisions shall have no effect on
payments or benefits otherwise due or payable to the Executive or on the Executive’s behalf, which are not on account of the Executive’s
termination from employment with the Company, including as a result of the Executive’s death. Furthermore, if the Company reasonably
determines that the Executive is a “Specified Employee” as defined by Section 409A, upon termination of Executive’s
employment for any reason other than death (whether by resignation or otherwise), no amount may be paid to the Executive earlier than
six months after the date of termination of Executive’s employment if such payment would violate Section 409A and the regulations
issued thereunder, and payment shall be made, or commence to be made, as the case may be, on the date that is six months and one day after
the termination of Executive’s employment. Each payment made under this Agreement shall be designated as a “separate payment”
within the meaning of Section 409A.

 

    2

     

    

 

5.
TERMINATION.

 

5.1 Termination Due
to Death or Disability.

 

5.1.1 Death. This
Agreement shall terminate immediately upon the death of Executive. Upon Executive’s death, Executive’s estate or Executive’s
legal representative, as the case may be, shall be entitled to Executive’s accrued and unpaid Salary and vacation as of the date
of Executive’s death, plus all other compensation and benefits that were vested through the date of Executive’s death.

 

5.1.2 Disability.
In the event of Executive’s Disability, this Agreement shall terminate and Executive shall be entitled to (a) accrued and unpaid
vacation through the first date that a Disability is determined; and (b) all other compensation and benefits that were vested through
the first date that a Disability has been determined.

 

5.2 Termination .
Both the Company and the Executive may terminate the employment hereunder by delivery of written notice to the other party at least thirty
(30) days prior to termination date or with a shorter notice period if agreed upon by the Parties. At Company’s sole discretion,
it may substitute thirty (30) days salary in lieu of such written notice. However, that in the event of a breach of this Agreement by
the Executive or an event which would constitute “Cause”, the Company may immediately terminate this Agreement upon written
notice with no waiting period or substituting salary. Upon the effective date of termination under this Section 5.2, Executive shall be
entitled to (a) accrued and unpaid vacation through such effective date; and (b) all other compensation and benefits that were vested
through such effective date.

 

5.3 Notice of Termination.
Any termination of the Employment by the Company or the Executive shall be communicated by a notice in accordance with Section 8.4 of
this Agreement (the “Notice of Termination”).

 

5.4 Payment. The
Executive shall not be entitled to severance payments upon any termination provided in Section 5 herein. Except as otherwise provided
in this Agreement, any payments to which the Executive shall be entitled under this Section 5, including, without limitation, any economic
equivalent of any benefit, shall be made as promptly as possible following the Date of Termination, but in no event more than 30 days
after the Date of Termination. If the amount of any payment due to the Executive cannot be finally determined within thirty (30) days
after the Date of Termination, such amount shall be reasonably estimated on a good faith basis by the Company and the estimated amount
shall be paid no later than thirty (30) days after such Date of Termination. As soon as practicable thereafter, the final determination
of the amount due shall be made and any adjustment requiring a payment to Executive shall be made as promptly as practicable. The payment
of any amounts under this Section 5 shall not affect Executive’s rights to receive any workers’ compensation benefits.

 

6. EXECUTIVE’S REPRESENTATION.
The Executive represents and warrants to the Company that: (a) he is subject to no contractual, fiduciary or other obligation which may
affect the performance of his duties under this Agreement; (b) he has terminated, in accordance with their terms, any contractual obligation
which may affect his performance under this Agreement; and (c) his employment with the Company will not require him to use or disclose
proprietary or confidential information of any other person or entity.

 

7.
NON-COMPETITION: NON-DISCLOSURE; INVENTIONS.

 

7.1 Trade Secrets.
Executive acknowledges that his employment position with the Company is one of trust and confidence. Executive further understands and
acknowledges that, during the course of Executive’s employment with the Company, Executive will be entrusted with access to certain
confidential information, specialized knowledge and trade secrets which belong to the Company, or its subsidiaries, including, but not
limited to, their methods of operation and developing customer base, its manner of cultivating customer relations, its practices and preferences,
current and future market strategies, formulas, patterns, patents, devices, secret inventions, processes, compilations of information,
records, and customer lists, all of which are regularly used in the operation of their business and which Executive acknowledges have
been acquired, learned and developed by them only through the expenditure of substantial sums of money, time and effort, which are not
readily ascertainable, and which are discoverable only with substantial effort, and which thus are the confidential and the exclusive
Property of the Company and its subsidiaries (hereinafter “Trade Secrets”). Executive covenants and agrees to use his best
efforts and utmost diligence to protect those Trade Secrets from disclosure to third parties. Executive further acknowledges that, absent
the protections afforded the Company and its subsidiaries in Section 7, Executive would not be entrusted with any of such Trade Secrets.
Accordingly, Executive agrees and covenants (which agreement and covenant shall survive the termination of this Agreement regardless of
the reason) as follows:

 

7.1.1 Executive will at no
time take any action or make any statement that will disparage or discredit the Company, any of its subsidiaries or their products or
services;

 

    3

     

    

 

7.1.2 During the period of
Executive’s employment with the Company and for sixty (60) months immediately following the termination of such employment, Executive
will not disclose or reveal to any person, firm or corporation other than in connection with the business of the Company and its subsidiaries
or as may be required by law, any Trade Secret used or useable by the Company or any of its subsidiaries, divisions or Affiliates (collectively
the “Companies”) in connection with their respective businesses, known to Executive as a result of his employment by
the Company, or other relationship with the Companies, and which is not otherwise publicly available. Executive further agrees that during
the term of this Agreement and at all times thereafter, he will keep confidential and not disclose or reveal to any person, firm or corporation
other than in connection with the business of the Companies or as may be required by applicable law, any information received by him during
the course of his employment with regard to the financial, business, or other affairs of the Companies, their respective officers, directors,
customers or suppliers which is not publicly available;

 

7.1.3 Upon the termination
of Executive’s employment with the Company, Executive will return to the Company all documents, customer lists, customer information,
product samples, presentation materials, drawing specifications, equipment and other materials relating to the business of any of the
Companies, which Executive hereby acknowledges are the sole and exclusive property of the Companies or any one of them. Nothing in this
Agreement shall prohibit Executive from retaining, at all times any document relating to his personal entitlements and obligations, his
rolodex, his personal correspondence files; and any additional personal property;

 

7.1.4 During the term of the
Agreement and, for a period of three (3) months immediately following the termination of the Executive’s employment with the Company,
Executive will not: compete, or participate as a shareholder, director, officer, partner (limited or general), trustee, holder of a beneficial
interest, employee, agent of or representative in any business competing directly with the Companies without the prior written consent
of the Company, which may be withheld in the Company’s sole discretion; provided, however, that nothing contained herein shall be
construed to limit or prevent the purchase or beneficial ownership by Executive of less than five percent of any security registered under
Section 12 or 15 of the Securities Exchange Act of 1934;

 

7.1.5 During the term of the Agreement and, for
a period of eighteen (18) months immediately following the termination of the Executive’s employment with the Company, Executive
will not:

 

7.1.5.1 solicit or accept
competing business from any customer of any of the Companies or any person or entity known by Executive to be or have been, during the
preceding 18 months, a customer or Prospective Customer of any of the Companies without the prior written consent of the Company;

 

7.1.5.2 encourage, request
or advise any such customer or Prospective Customer of any of the Companies to withdraw or cancel any of their business from or with any
of the Companies; or

 

7.1.6 Executive will not during the period of his
employment with the Company and, subject to the provisions hereof for a period of eighteen (18) months immediately following the termination
of Executive’s employment with the Company,

 

7.1.6.1 conspire with any
person employed by any of the Companies with respect to any of the matters covered by this Section 7;

 

7.1.6.2 encourage, induce
or solicit any person employed by any of the Companies to facilitate Executive’s violation of the covenants contained in this Section
7;

 

    4

     

    

 

7.1.6.3 assist any entity
to solicit the employment of any employee of any of the Companies; or

 

7.1.6.4 employ or hire any
employee of any of the Companies, or solicit or induce any such person to join the Executive as a partner, investor, coventurer, or otherwise
encourage or induce them to terminate their employment with any of the Companies.

 

7.2 Executive expressly acknowledges
that all of the provisions of this Section 7 of this Agreement have been bargained for and Executive’s agreement hereto is an integral
part of the consideration to be rendered by the Executive which justifies the rate and extent of the compensation provided for hereunder.

 

7.3 Executive acknowledges and
agrees that a violation of any one of the covenants contained in this Section 7 shall cause irreparable injury to the Company, that the
remedy at law for such a violation would be inadequate and that the Company shall thus be entitled to temporary injunctive relief to enforce
that covenant until such time that a court of competent jurisdiction either (a) grants or denies permanent injunctive relief or (b) awards
other equitable remedy(s) as it sees fit.

 

7.4 Successors.

 

7.4.1 Executive.
This Agreement is personal to Executive and, without the prior express written consent of the Company, shall not be assignable by Executive,
except that Executive’s rights to receive any compensation or benefits under this Agreement may be transferred or disposed of pursuant
to testamentary disposition, intestate succession or a qualified domestic relations order or in connection with a Disability. This Agreement
shall inure to the benefit of and be enforceable by Executive’s estate, heirs, beneficiaries, and/or legal representatives.

 

7.4.2 The Company.
This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

7.5 Inventions and Patents.
The Company shall be entitled to the sole benefit and exclusive ownership of any inventions or improvements in products, processes, or
other things that may be made or discovered by Executive while he is in the service of the Company, and all patents for the same. During
the Term, Executive shall do all acts necessary or required by the Company to give effect to this section and, following the Term, Executive
shall do all acts reasonably necessary or required by the Company to give effect to this section. In all cases, the Company shall pay
all costs and fees associated with such acts by Executive.

 

8.
MISCELLANEOUS.

 

8.1 Indemnification.
The Company and each of its subsidiaries shall, to the maximum extent provided under applicable law, indemnify and hold Executive harmless
from and against any expenses, including reasonable attorney’s fees, judgments, fines, settlements and other legally permissible
amounts (“Losses”), incurred in connection with any proceeding arising out of, or related to, Executive’s employment
by the Company, other than any such Losses incurred as a result of Executive’s negligence or willful misconduct. The Company shall,
or shall cause a subsidiary thereof to, advance to Executive any expenses, including attorney’s fees and costs of settlement, incurred
in defending any such proceeding to the maximum extent permitted by applicable law. Such costs and expenses incurred by Executive in defense
of any such proceeding shall be paid by the Company or applicable subsidiary in advance of the final disposition of such proceeding promptly
upon receipt by the Company of (a) written request for payment; (b) appropriate documentation evidencing the incurrence, amount and nature
of the costs and expenses for which payment is being sought; and (c) an undertaking adequate under applicable law made by or on behalf
of Executive to repay the amounts so advanced if it shall ultimately be determined pursuant to any non-appealable judgment or settlement
that Executive is not entitled to be indemnified by the Company or any subsidiary thereof. the Company will provide Executive with coverage
under all director’s and officer’s liability insurance policies which is has in effect during the Term, with no deductible
to Executive.

 

8.2 Applicable Law.
Except as may be otherwise provided herein, this Agreement shall be governed by and construed in accordance with the laws of the State
of New York, applied without reference to principles of conflict of laws.

 

    5

     

    

 

8.3 Amendments.
This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective
successors or legal representatives.

 

8.4 Notices. All
notices and other communications hereunder shall be in writing and shall be given by hand-delivery to the other party or by registered
or certified mail, return receipt requested, postage prepaid, addressed as follows:

 

If to the Executive:

 

____________________________

______________________

_______________________

Attention: Mr. Xiaolai Li

Email: _________________ 

 

If to the Company:

 

3rd Floor, Borough A, Block A. No.181

South Taibai Road, Xi’an, Shaanxi Province,

People’s Republic of China 710065

Attn: Mr. Zhuoyu Li, Chief Executive Officer

Tel: (86-29) 8826-6368

 

Or to such other address as either party shall
have furnished to the other in writing in accordance herewith. Notices and communications shall be effective when actually received by
the addressee.

 

8.5 Withholding.
The Company may withhold from any amounts payable under the Agreement, such federal, state and local income, unemployment, social security
and similar employment related taxes and similar employment related withholdings as shall be required to be withheld pursuant to any applicable
law or regulation.

 

8.6 Severability.
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision
of this Agreement, and any such provision which is not valid or enforceable in whole shall be enforced to the maximum extent permitted
by law.

 

8.7 Captions. The
captions of this Agreement are not part of the provisions and shall have no force or effect.

 

8.8 Entire Agreement.
This Agreement contains the entire agreement among the parties concerning the subject matter hereof and supersedes all prior agreements,
understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto.

 

8.9 Survivorship.
The respective rights and obligations of the parties hereunder shall survive any termination of this Agreement or the Executive’s
employment hereunder to the extent necessary to the intended preservation of such rights and obligations.

 

8.10 Waiver. Either
Party’s failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such
provision or provisions, or prevent that party thereafter from enforcing each and every other provision of this Agreement.

 

8.11 Joint Efforts/Counterparts.
Preparation of this Agreement shall be deemed to be the joint effort of the parties hereto and shall not be construed more severely against
any party. This Agreement may be signed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one and the same instrument.

 

8.12 Representation
by Counsel. Each Party hereby represents that it has had the opportunity to be represented by legal counsel of its choice in connection
with the negotiation and execution of this Agreement.

 

-- Signature page follows --

 

    6

     

    

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of
the day and year first above written.

 

	EMPLOYEE:	 	CHINA GREEN AGRICULTURE, INC.
	 	 	 
	/s/ Xiaolai Li	 	/s/ Zhuoyu Li
	Xiaolai Li	 	Zhuoyu Li
	 	 	Chairman of the Board of Directors, Chief Executive Officer, and President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]